NeuroClin Ltd reposted this
Today is another important moment in the global fight against dementia with the announcement of Donanemab becoming the second drug to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the treatment of early-stage Alzheimer's disease. Similar to Lecanemab, a drug approved by the MHRA in August, Donanemab has been shown to slow down the progression of Alzheimer’s disease in clinical trials. We have been heavily involved over the last 25 years in the development and research of treatments for numerous degenerative neurological conditions and view the license granted for Donanemab as another landmark moment in the quest to find a cure for Alzheimer’s disease. We look forward to our essential ongoing work, continuing to contribute to the growing body of research on disease modifying treatments for dementia and help national health bodies become more informed when considering the merits of making this drug available to the wider public. https://lnkd.in/d6qNZDfB